AU Patent

AU2013204187B2 — Nanoparticle comprising rapamycin and albumin as anticancer agent

Assigned to Abraxis Bioscience LLC · Expires 2015-10-01 · 11y expired

What this patent protects

This application relates to methods and compositions for treating, stabilizing, preventing, and/or delaying cancer using nanoparticles that comprise rapamycin or a derivative thereof. The application further provides combination therapy methods of treating cancer comprising admin…

USPTO Abstract

This application relates to methods and compositions for treating, stabilizing, preventing, and/or delaying cancer using nanoparticles that comprise rapamycin or a derivative thereof. The application further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013204187B2
Jurisdiction
AU
Classification
—
Expires
2015-10-01
Drug substance claim
No
Drug product claim
No
Assignee
Abraxis Bioscience LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.